LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
34 funds hold it · Insiders net selling
Net selling: insiders sold $59.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 5, 2026
Financial period
Q1 FY27
Earnings per share
$2.94 expected
Revenue
$66.51B expected
Estimates as of Nov 11, 2026
EPS expected
$2.93 to $3.64
Revenue expected
10 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 5, 2026 | $3.26est. $2.94 | +10.91%beat | $67.50Best. $66.51B+1.49% | +5.5%from $64.01B |
| Jun 30, 2026Reported Aug 11, 2026 | $2.91est. $2.42 | +20.25%beat | $63.67Best. $65.11B-2.20% | +5.8%from $60.16B |
| Mar 31, 2026Reported Apr 30, 2026 | $3.17est. $2.79 | +13.70%beat | $60.94BAlpha Vantage | +11.0%from $54.88B |
| Dec 31, 2025Reported Feb 5, 2026 | $2.63est. $2.37 | +11.17%beat | $65.44BAlpha Vantage | +18.4%from $55.26B |
| Sep 30, 2025Reported Oct 30, 2025 | $2.55est. $2.17 | +17.51%beat | $64.01BSEC filing | +22.4%from $52.28B |
| Jun 30, 2025Reported Aug 12, 2025 | $2.08est. $2.03 | +2.46%beat | $60.16BAlpha Vantage | +0.8%from $59.71B |
| Mar 31, 2025Reported May 1, 2025 | $2.35est. $2.15 | +9.30%beat | $54.88BAlpha Vantage | 0.0%from $54.87B |
| Dec 31, 2024Reported Jan 30, 2025 | $1.93est. $1.76 | +9.66%beat | $55.26BAlpha Vantage | -3.8%from $57.44B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $65.44B | $60.94B | $63.86B | $67.51B |
| Cost of what it sold | $63.23B | $58.44B | $61.11B | $64.92B |
| Gross profit | $2.21B | $2.50B | $2.75B | $2.60B |
| What it spent | ||||
| Sales and admin | $1.50B | $1.54B | $1.63B | $1.59B |
| Other operating costs | — | $447.0M | $392.0M | $248.0M |
| Total operating expenses | $1.50B | $1.99B | $2.02B | $1.84B |
| What was left | ||||
| Operating profit | $707.0M | $509.0M | $729.0M | $753.0M |
| Interest on debt | $88.0M | $101.0M | $79.0M | $73.0M |
| Profit before tax | $630.0M | $392.0M | $554.0M | $688.0M |
| Tax | $159.0M | $12.0M | $154.0M | $132.0M |
| Net profit | $471.0M | $399.0M | $394.0M | $554.0M |
| EBITDA | $776.0M | $741.0M | $1.05B | $1.01B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
If You Invested $100 In Cardinal Health Stock 5 Years Ago, You Would Have This Much Today
BullishNov 10Henry Schein (NASDAQ:HSIC) Q3 2026: EPS Beat, Guidance Raised
NeutralNov 10Can Cardinal Health Stock Repeat Its Last Five Years?
Leans bullishNov 10DataMEDS Completes First Compounded Peptide Sale
Leans bullishNov 9TD Cowen raises Cardinal Health stock price target on broad profit growth
BullishNov 9Weekly Recap: Albumin revenue falls and Canadian collections restart
Leans bearishNov 9Cardinal Health (CAH) Lifts Guidance As Investors Ask If The Story Is Fully Valued
Leans bullishNov 7McKesson Q2 Earnings Call Highlights
NeutralNov 734 macro signals shaping CAH right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
